Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer.
The value of pharmacogenetic information at an individual level seems self-evident; demonstrating the value to the individual across a population appears to be much more difficult to demonstrate. Future studies should avoid single gene-drug pairs and a limited number of population-specific alleles that are insufficient to capture all relevant genetic variation within diverse populations, such as CYP2C9*2 and *3. Robust associations between cytochrome P450 (CYP) genotypes and treatment response require knowledge of drug exposure.